Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031307 | 0.93 | F10 (0.51) | F10LMNAMAPK1KMT2ACCKBR | |
| SCHEMBL3032269 | 0.93 | F10 (0.59) | F10LMNAMAPK1KMT2ACCKBR | |
| SCHEMBL3031666 | 0.92 | F10 (0.58) | F10LMNAMAPK1KMT2A | |
| SCHEMBL8250835 | 0.92 | F10 (0.50) | F10LMNAMAPK1KMT2ACCKBR | |
| SCHEMBL8252693 | 0.91 | CCKBR (0.51) | F10LMNAMAPK1KMT2ACCKBR | |
| SCHEMBL2571454 | 0.91 | F10 (0.54) | F10LMNAMAPK1KMT2ACCKBR | |
| SCHEMBL2563403 | 0.91 | F10 (0.49) | F10LMNAMAPK1KMT2ACCKBR | |
| SCHEMBL3023943 | 0.90 | F10 (0.49) | F10LMNAMAPK1KMT2A | |
| SCHEMBL3038496 | 0.89 | F10 (0.49) | F10LMNAMAPK1KMT2ACCKBR | |
| SCHEMBL3028368 | 0.89 | F10 (0.48) | F10LMNAMAPK1KMT2ACCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| WO-2007003536-A1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GNMT | F10 1271/4885LMNA 2509/4885MAPK1 2324/4885 |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | F10 1439/4885LMNA 2832/4885MAPK1 2507/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | F10 1439/4885LMNA 2832/4885MAPK1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.